Targetable epigenetic mechanism driving Cutaneous T cell Lymphoma

驱动皮肤T细胞淋巴瘤的靶向表观遗传机制

• 批准号: 10800864
• 负责人: Jose R Conejo-Garcia
• 金额: $ 38.8万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-02 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10800864
• 关键词: AT Rich Sequence; Ablation; American Cancer Society; Automobile Driving; Binding Proteins; Biological; Blood; CD4 Positive T Lymphocytes; Cancer Center; Chromatin; Clinic; Clinical; Clinical Investigator; Collection; Cutaneous T-cell lymphoma; Deacetylation; Deletion Mutation; Dermatology; Diagnosis; Disease; Down-Regulation; Drug Combinations; Epigenetic Process; Etiology; Functional disorder; GPR2 gene; Genetic Transcription; Genomics; Goals; Growth and Development function; Hematologist; Hematology; Histone Deacetylase; Histone Deacetylation; Homing; Human; Immunologist; Intervention; Lymphocyte; Lymphoma cell; Lysine; Malignant - descriptor; Mature T-Lymphocyte; Methyltransferase; Molecular; Oncogenic; Organ; Outcome; Pathogenesis; Pathogenicity; Patients; Peripheral; Phosphorylation; Point Mutation; Rare Diseases; Repression; Role; Sampling; Scheme; Sezary Syndrome; Sezary cell; Signal Transduction; Skin; Small-Cell Lymphoma; Specimen; Stat5 protein; Survival Rate; T-Cell Development; T-Cell Lymphoma; T-Lymphocyte; Testing; Therapeutic; Thymus Gland; Tumor Suppressor Proteins; Work; chemokine receptor; clinical translation; cytokine; derepression; design; effective intervention; effective therapy; epigenetic drug; epigenetic silencing; histone methylation; inhibitor; insight; leukemia; lymph nodes; malignant phenotype; mouse model; notch protein; novel; overexpression; palliative; prevent; programs; promoter; transcription factor

ABSTRACT The lack of a clear understanding of the pathophysiology of Cutaneous T cell Lymphoma (CTCL) and in particular its aggressive leukemic form Sézary Syndrome, has impeded therapeutic advances, and current treatments are only palliative. Although CTCL is a relatively rare disease, Moffitt Cancer Center Malignant Hematology and USF Dermatology Departments manages about 100 new patients with CTCL annually. This study represents a concerted effort by a team of clinical investigators and translational immunologists at Moffitt to identify new effective treatments for CTCL patients with aggressive disease, based on the discovery of key molecular regulators of Sézary Syndrome development and growth. Specifically, our new mouse models indicate that Special AT-rich region binding protein 1 (SATB1), a master genomic organizer and a key regulator of T-cell development and maturation, prevents mature T cell malignization by repressing crucial pathogenic drivers of Sézary cells. Our central hypothesis is that SATB1 acts as a tumor suppressor in CTCL, by repressing STAT5 activation, chemokine receptors that govern T cell homing to the skin and transcription factors commonly de-regulated in malignant T cells. Accordingly, restoring SATB1 expression by targeting histone methylation and de-acetylation will avert the malignant phenotype of Sézary cells. We will leverage a growing collection of aphaeresis specimens and unique mouse models to dissect the epigenetic mechanisms governing the pathogenesis of Sézary Syndrome, with the overarching goal of subsequently targeting them through more effective interventions in our clinic. In Aim 1, we will elucidate how SATB1 silencing drives the pathogenesis of CTCL. Based on our preliminary results, our hypothesis is that Satb1 silencing cooperates with Notch signaling to elicit a STAT5-, CCR10-, IKZF2/HELIOS-dependent transcriptional program leading to the progressive expansion, skin homing and malignant transformation of post-thymic CD4 T cells. In Aim 2, we will define the complementary mechanisms leading to epigenetic silencing of the SATB1 locus in Sézary Syndrome. We will test the hypothesis that SATB1 is silenced in Sézary cells through a combination of histone methylation at K27 and K9 that, along with and lysine de-acetylation, resulting in significant changes in chromatin accessibility. In Aim 3, we will leverage our new biological understanding to identify the combination of epigenetic drugs that more effectively restore SATB1 expression and thwart oncogenic signals in Sézary cells. Our work will exert a profound effect in the field by elucidating how epigenetic repression of the master genomic organizer SATB1 governs the malignant transformation of mature CD4 T cells in coordination with NOTCH signaling, leading to fatal skin accumulation of lymphocytes in Sézary patients. This mechanistic insight will inform the most effective combination of drugs needed to de-repress the SATB1 locus and antagonize oncogenic signals, which will overturn malignant Sézary cells. This biological understanding will be followed by clinical interventions at Moffitt for patients with aggressive CTCL, including Sézary Syndrome.

摘要